| Background:Short disease is a disease of abnormal height, whose main symptom is short stater, caused by the endocrine metabolic abnormalities, hereditary disease, poor nutrition, mental disorders or other reasons. The incidence of short disease is for4.87%male and4.19%female at present in our country. It can cause final height loss,and psychological barriers such as inferiority. There would be other comorbid symptoms according to different causes,which influent patients health seriously. At present the main treatment of short disease is to eliminate reasons. Growth hormone is an important hormone promoting the linear growth of human body. Recombinant human growth hormone (rhGH) is the main drug to treat short disease. The indications of rhGH approvaled by the United States food and drug administration FDA include children’s growth hormone deficiency (GHD), Turner syndrome(TS), adult GHD replacement therapy, Prader-Willi syndrome, and less than gestational age (SGA), idiopathic short stature (ISS), SHOX gene but not with GHD lack of children. With rhGH widely applicated in clinical, people pay more attention to the safety problem of rhGH long-term treatment.Traditional Chinese medicine treatment on short disease is lack in systematic research.There are only compound preparations, acupuncture methods used in clinical as small samples, no large sample or effective research including control. Therefore, it is very important of further study of traditional Chinese medicnine and western morden medicine combined treatments for short disease. This study was to choose to promote the growth of children of the small clinical the most effective, one of the most widely applied recombinant human growth hormone, monitoring the change of platelet parameters before and after treatment, maintenance of small children to provide data to support health disease.Objective:the clinical case analysis, to observe short stater children using recombinant human growth hormone (rhGH) after treatment, the change of platelet parameters, monitoring growth hormone treatment short disease promote the growth of effective treatment of children of the side effects, to observe the safety of rhGH treatment.Methods:18pediatric patients with growth hormone deficiency (GHD),10with idiopathic short stature (ISS) and5with Turner syndrome (TS)were selected in random. Each of them was treated with rhGH for6months. Collected Fasting vein blood before and after6months of rhGH therapy, evaluat the rhGH therapy effects of parameters of platelets Results:The platelet count (PLT) in33children with short stature increased in a statistically significant (P<0.01) after treatment. PLT increased greater than the normal range in a significant difference (P<0.05) in six cases of ISS children and4cases of TS children after treatment. And PLT increased greater than the normal range after treatment in9cases of GHD, but there was no statistically significant. The incidence of PLT increasing greater than the normal range between three groups of patients after treatment had no significant differences. Before and after treatment, platelet distribution width,(PDW), average platelet volume (MPV), big platelet ratio (P-LCR), platelet deposited (PCT) changes had no statistically significant.Conclusion:PLT of short stature children was increased after six months of rhGH treatment, part of them PLT was increased above the normal range, which may cause blood high pour-point state and increase the thrombosis risk. Monitoring changes of platelet count have an important significance in improving the safety application to growth hormone. The mechanism of rhGH increasing platelet production in children with short stature after treatment may related to the remedial adjustment on glucose and lipid metabolism, but the exact mechanism needs further research. |
PDF Full Text Request